Reditux is the trade name of a biosimilar version of ‘rituximab’, an anti-CD20 antibody used in the treatment of certain lymphomas, leukaemias and rheumatoid arthritis. Reditux is produced by Dr. Reddy’s Laboratories, one of India’s largest pharmaceutical companies.
Reditux used in the treatment of certain lymphomas, leukaemias and rheumatoid arthritis.
Reditux belongs to a drug group called antineoplastic agent. The major component of this drug is rituximab. It may be used unaccompanied or together with other drugs for treating non-hodgkin’s lymphoma. This medicine is also given for the treatment of rheumatoid arthritis.
Reditux (Rituximab) is not meant for those who have a severe infection at present. This drug is also not recommended for patients having known hypersensitivity to any component in this medication or to rat or mouse protein. Patients who have RA and who have not formerly used some other medications (e.g., tumor necrosis factor [TNF] antagonists) should not receive this drug.